Sun-Novo(SH:688621) Ge Long Hui A P P·2026-02-27 12:47Core Insights - The company reported a revenue of 1.218 billion yuan for the fiscal year 2025, representing a year-on-year growth of 12.92% [1] - The net profit attributable to the parent company was 196 million yuan, with a year-on-year increase of 10.53% [1] - The net profit attributable to the parent company after deducting non-recurring gains and losses was 184 million yuan, reflecting an 11.52% year-on-year growth [1] Revenue and Profit Drivers - The company's revenue and profit growth were driven by the deep layout of its innovative drug pipeline, realization of value from licensing collaborations, and the synergistic support of its integrated service model [1] - The focus on innovative drug research and development with global intellectual property rights has led to a pipeline matrix that includes over 20 first-class new drugs targeting major diseases such as cancer and pain [1] - The integration of clinical and preclinical services, along with a robust quality management system and a clinical cooperation network with over 300 hospitals, has facilitated efficient project advancement [1] Licensing and Strategic Initiatives - Licensing collaborations and revenue sharing have become key drivers of profit growth, with significant income generated from the licensing of pipelines such as STC007 and STC008, contributing to high-margin revenue sources [2] - The implementation of the "R&D services + pipeline cultivation + new quality industrial chain" strategy has provided a solid foundation for business growth, steadily enhancing the company's profitability [2]